ea0049ep605 | Diabetes therapy | ECE2017
, Park Sungwoo
, Lee Mookyu
, Yoon Kunho
Background and aims: To evaluate the efficacy and safety of the newly developed dipeptidyl peptidase-4 (DPP-4) inhibitor evogliptin in drug-naïve patients with inadequately controlled type 2 diabetes.Materials and methods: In randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase III study, 160 patients with type 2 diabetes were randomized to evogliptin 5 mg or placebo for 24 weeks. The primary efficacy outcome measure was ...